Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease

Clinica Chimica Acta

Volumn 413, Issue 15-16, 2012, Pages 1190-1193

  Yilmaz, Yusuf ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

Biomarkers; Hemoglobin; Nonalcoholic fatty liver disease; Proteomics; Serum

Indexed keywords

BIOLOGICAL MARKER; HEMOGLOBIN; PROTEOME;

BIOINFORMATICS; BLOOD ANALYSIS; BLOOD SAMPLING; DATA MINING; DIAGNOSTIC VALUE; FUNCTIONAL PROTEOMICS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERMETHOD COMPARISON; LABORATORY TEST; LIVER BIOPSY; LIVER INJURY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS;

BIOLOGICAL MARKERS; FATTY LIVER; HEMOGLOBINS; HUMANS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84861338095     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.04.019     Document Type: Review

References (41)

1. Law K., Brunt E.M. Nonalcoholic fatty liver disease. Clin Liver Dis 2010, 14:591-604.
2. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
3. Dowman J.K., Tomlinson J.W., Newsome P.N. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2011, 33:525-540.
4. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007, 25:883-889.
5. Vanni E., Bugianesi E., Kotronen A., et al. From the metabolic syndrome to NAFLD or vice versa?. Dig Liver Dis 2010, 42:320-330.
6. Bugianesi E., Moscatiello S., Ciaravella M.F., Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010, 16:1941-1951.
7. Albano E., Mottaran E., Occhino G., Reale E., Vidali M. Review article: role of oxidative stress in the progression of non-alcoholic steatosis. Aliment Pharmacol Ther 2005, 22(Suppl. 2):71-73.
8. McCullough A.J. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006, 40(Suppl. 1):S17-S29.
9. Smith B.W., Adams L.A. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci 2011, 48:97-113.
10. Straub B.K., Schirmacher P. Pathology and biopsy assessment of non-alcoholic fatty liver disease. Dig Dis 2010, 28:197-202.
11. Brunt E.M. Non-alcoholic fatty liver disease: what's new under the microscope?. Gut 2011, 60:1152-1158.
12. Ali R., Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 2009, 41:265-278.
13. Yilmaz Y., Ulukaya E. Toward a biochemical diagnosis of NASH: insights from pathophysiology for distinguishing simple steatosis from steatohepatitis. Curr Med Chem 2011, 18:725-732.
14. Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther 2009, 30:1103-1109.
15. Estep J.M., Birerdinc A., Younossi Z. Non-invasive diagnostic tests for non-alcoholic fatty liver disease. Curr Mol Med 2010, 10:166-172.
16. Myers R.P. Noninvasive diagnosis of nonalcoholic fatty liver disease. Ann Hepatol 2009, 8(Suppl. 1):S25-S33.
17. Adams L.A., Feldstein A.E. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. J Dig Dis 2011, 12:10-16.
18. Yilmaz Y., Kedrah A.E., Ozdogan O. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J Gastroenterol 2009, 15:4387-4391.
19. Tamimi T.I., Elgouhari H.M., Alkhouri N., et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 2011, 54:1224-1229.
20. Younossi Z.M., Page S., Rafiq N., et al. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 2011, 21:431-439.
21. Cécile M., Davide D.E., Antonin B., Catherine B., Antoinette L. Non-alcoholic steatohepatitis: new insights from OMICS studies. Curr Pharm Biotechnol 2012, 13:726-735.
22. Yu C., Xu C., Xu L., Yu J., Miao M., Li Y. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol 2012, 56:241-247.
23. Uto H., Kanmura S., Takami Y., Tsubouchi H. Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers. Proteome Sci 2010, 8:70.
24. Bell L.N., Theodorakis J.L., Vuppalanchi R., et al. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 2010, 51:111-120.
25. Ulukaya E., Yilmaz Y., Moshkovskii S., et al. Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Scand J Gastroenterol 2009, 44:1471-1476.
26. Baranova A., Liotta L., Petricoin E., Younossi Z.M. The role of genomics and proteomics: technologies in studying non-alcoholic fatty liver disease. Clin Liver Dis 2007, 11:209-220.
27. Trak-Smayra V., Dargere D., Noun R., et al. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut 2009, 58:825-832.
28. Younossi Z.M., Baranova A., Ziegler K., et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005, 42:665-674.
29. Teng P.N., Bateman N.W., Hood B.L., Conrads T.P. Advances in proximal fluid proteomics for disease biomarker discovery. J Proteome Res 2010, 9:6091-6100.
30. Ray S., Reddy P.J., Jain R., et al. Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics 2011, 11:2139-2161.
31. Horvatovich P.L., Bischoff R. Current technological challenges in biomarker discovery and validation. Eur J Mass Spectrom (Chichester, Eng) 2010, 16:101-121.
32. De Bock M., de Seny D., Meuwis M.A., et al. Challenges for biomarker discovery in body fluids using SELDI-TOF-MS. J Biomed Biotechnol 2010, 2010:906082.
33. Dowling P., Meleady P., Henry M., Clynes M. Recent advances in clinical proteomics using mass spectrometry. Bioanalysis 2010, 2:1609-1615.
34. Hawkridge A.M., Muddiman D.C. Mass spectrometry-based biomarker discovery: toward a global proteome index of individuality. Annu Rev Anal Chem (Palo Alto Calif) 2009, 2:265-277.
35. Nobili V., Alkhouri N., Alisi A., et al. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009, 7:575-579.
36. Xu L., Xu C.F., Yu C.H., Miao M., Li Y.M. Haemoglobin and non-alcoholic fatty liver disease: further evidence from a population-based study. Gut 2009, 58:1706-1707.
37. Yilmaz Y., Senates E., Ayyildiz T., et al. Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. Eur J Clin Invest 2012, 42:411-418.
38. Dong H., Lu F., Wang N., Zou X., Rao J. Type 2 diabetic patients with non-alcoholic fatty liver disease exhibit significant haemorheological abnormalities. Front Med 2011, 5:288-293.
39. Zhang Q., Faca V., Hanash S. Mining the plasma proteome for disease applications across seven logs of protein abundance. J Proteome Res 2011, 10:46-50.
40. Bielow C., Gröpl C., Kohlbacher O., Reinert K. Bioinformatics for qualitative and quantitative proteomics. Methods Mol Biol 2011, 719:331-349.
41. Martens L. Bioinformatics challenges in mass spectrometry-driven proteomics. Methods Mol Biol 2011, 753:359-371.